Wedbush restated their buy rating on shares of Allena Pharmaceuticals (NASDAQ:ALNA) in a report released on Monday, December 18th. Wedbush also issued estimates for Allena Pharmaceuticals’ Q4 2017 earnings at ($0.28) EPS, Q1 2018 earnings at ($0.37) EPS, Q2 2018 earnings at ($0.37) EPS, Q3 2018 earnings at ($0.37) EPS, Q4 2018 earnings at ($0.37) EPS, FY2018 earnings at ($1.48) EPS, FY2019 earnings at ($1.88) EPS, FY2020 earnings at ($2.09) EPS and FY2021 earnings at ($2.59) EPS.
“We reiterate our Underperform rating and $37 price target post 3Q:17 and after speaking with management. We continue to see minimal value from Eagle’s pipeline and expect the company to acquire an asset.”,” Wedbush’s analyst commented.
Other equities research analysts also recently issued research reports about the stock. Jefferies Group initiated coverage on shares of Allena Pharmaceuticals in a research report on Monday, November 27th. They issued a buy rating and a $22.00 target price for the company. Cowen initiated coverage on shares of Allena Pharmaceuticals in a report on Monday, November 27th. They set an outperform rating on the stock. Finally, Credit Suisse Group initiated coverage on shares of Allena Pharmaceuticals in a report on Monday, November 27th. They set an outperform rating and a $22.00 price target on the stock.
Allena Pharmaceuticals (NASDAQ:ALNA) traded up $0.06 during mid-day trading on Monday, reaching $10.24. 182,542 shares of the company’s stock were exchanged, compared to its average volume of 69,067. Allena Pharmaceuticals has a 12 month low of $8.66 and a 12 month high of $15.40. The company has a current ratio of 4.83, a quick ratio of 4.83 and a debt-to-equity ratio of -0.09. The stock has a market cap of $210.42 and a P/E ratio of -9.94.
In related news, Director James N. Topper purchased 500,000 shares of the firm’s stock in a transaction on Monday, November 6th. The shares were bought at an average cost of $14.00 per share, for a total transaction of $7,000,000.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder Bessemer Venture Partners Vii purchased 36,000 shares of the firm’s stock in a transaction on Monday, November 6th. The stock was bought at an average price of $14.00 per share, for a total transaction of $504,000.00. The disclosure for this purchase can be found here.
Allena Pharmaceuticals Company Profile
Allena Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on developing and commercializing non-systemic oral protein therapeutics to treat metabolic and orphan diseases, with a particular focus on nephrologic and urologic conditions. Its lead product candidate, ALLN-177, is in an ongoing Phase II clinical trial and is being developed for the chronic management of hyperoxaluria and kidney stones.
Receive News & Ratings for Allena Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allena Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.